首页> 美国卫生研究院文献>Neuro-oncology Advances >RADI-40. STEREOTACTIC RADIOSURGERY FOR BRAINSTEM METASTASES: AN ANALYSIS OF SINGLE FRACTION AND MULTI FRACTION TECHNIQUES
【2h】

RADI-40. STEREOTACTIC RADIOSURGERY FOR BRAINSTEM METASTASES: AN ANALYSIS OF SINGLE FRACTION AND MULTI FRACTION TECHNIQUES

机译:拉迪40。脑干转移瘤的立体定位放射外科:单组分和多组分技术的分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

PURPOSE: Utilization of stereotactic radiosurgery (SRS) for brainstem metastases (BSM) is increasing. Multi-fraction SRS (MF-SRS) is a potential means of obtaining therapeutic gain while limiting toxicity. However, most available data assesses only single-fraction SRS (SF-SRS). This study aims to evaluate the efficacy and safety of SF-SRS and MF-SRS for BSM. METHODS: Data was retrospectively collected for patients with BSM treated with SRS between 2003–2018 at a single institution. Kaplan-Meier method was used to evaluate overall survival (OS) and local control (LC). Independent t-test was used for correlations between groups. RESULTS: 29 patients (31 lesions) were identified; 13 patients (15 lesions) underwent SF-SRS and 16 patients (16 lesions) underwent MF-SRS. Median follow-up was 6.8 months (1–80.8 months). Post-SRS MRI was available for 78% of patients. Median dose was 16Gy (12–18 Gy) for SF-SRS and 24 Gy (18–30 Gy) for MF-SRS. MF-SRS was delivered in a median of 3 fractions (3–5). There was a trend toward larger mean tumor volume with MF-SRS (1.297 vs 0.302mL, p=0.055). OS was 64.8% at 6 months and 49.3% at 12 months. LC was 90.9% at 6 months and 69.9% at 12 months. LC was similar between SF-SRS and MF-SRS at 6 months (100% vs 79.5%, p=0.143) and 12 months (50.0% vs 79.5%, p=0.812). Among the 4 patients who experienced local recurrence, 3 received salvage whole brain radiation and median OS was 8.1 months after LF. Distant CNS failures occurred in 40.3% of patients at 6 months and 72.4% at 12 months. Tumor volume >0.5 mL was associated with worse LC at 6 months (64.3% vs 100%, p=0.022). One patient developed symptomatic radiation necrosis (1/29 lesions, 3.4%) after MF-SRS. CONCLUSION: SRS is a safe and effective treatment for small BSM. Outcomes were not different between SF-SRS and MF-SRS but analysis is limited by small sample size.
机译:目的:立体定向放射外科(SRS)用于脑干转移(BSM)的应用正在增加。多级SRS(MF-SRS)是获得治疗收益同时限制毒性的潜在手段。但是,大多数可用数据仅评估单分数SRS(SF-SRS)。这项研究旨在评估SF-SRS和MF-SRS对BSM的疗效和安全性。方法:回顾性收集2003年至2018年间在单一机构接受SRS治疗的BSM患者的数据。 Kaplan-Meier方法用于评估总体生存率(OS)和局部控制(LC)。组间相关性采用独立t检验。结果:确定29例患者(31个病灶)。 SF-SRS患者13例(15个病灶),MF-SRS患者16例(16个病灶)。中位随访时间为6.8个月(1-80.8个月)。 SRS后MRI可用于78%的患者。 SF-SRS的中位剂量为16Gy(12–18 Gy),MF-SRS的中位剂量为24 Gy(18–30 Gy)。 MF-SRS的中位数为3个部分(3-5)。 MF-SRS有增加平均肿瘤体积的趋势(1.297 vs 0.302mL,p = 0.055)。 OS在6个月时为64.8%,在12个月时为49.3%。 LC在6个月时为90.9%,在12个月时为69.9%。 SF-SRS和MF-SRS在6个月(100%vs.79.5%,p = 0.143)和12个月(50.0%vs 79.5%,p = 0.812)时的LC相似。在经历局部复发的4例患者中,有3例接受了全脑放疗,LF后中位OS为8.1个月。在6个月时有40.3%的患者发生了中枢神经系统衰竭,在12个月时发生了72.4%的患者。肿瘤体积> 0.5 mL与6个月LC恶化相关(64.3%vs 100%,p = 0.022)。一名患者在MF-SRS后出现症状性放射坏死(1/29个病变,占3.4%)。结论:SRS是治疗小型BSM的安全有效方法。 SF-SRS和MF-SRS的结果无差异,但分析受限于样本量小。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号